Skip to Main Content

The latest broken link in the pharmaceutical supply chain has appeared in Hungary, where Teva Pharmaceuticals has suspended production at a plant following a crackdown by the US Food and Drug Administration.

The drug maker voluntarily halted work at its Godollo facility, which makes sterile injectable medicines, as “a precautionary measure” shortly after FDA inspectors visited last January, a Teva spokeswoman told us. The company is “working around the clock to restart manufacturing operations as soon as possible,” but she did not provide a timeline for when production may resume.


The shutdown only came to light after Hungarian regulators late last week issued a notice in an attempt to address concerns about drug shortages. Teva makes about 200 products at the facility, which is located outside of Budapest and can reportedly produce up to 200 million units of injectable drugs annually. The company invested about $110 million in the plant, which opened nearly four years ago.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.